Novel anti-platelet agent engineered by Australian researchers

Australian and US researchers have genetically engineered a novel antithrombotic drug, which binds only to activated platelets at the site of a thrombus. By only binding to activated platelets, not sealing platelets, there is no risk of bleeding complications with the recombinant fusion protein known as Targ-TAP. Targ-TAP consists of a single-chain antibody that targets ...

Already a member?

Login to keep reading.

© 2021 the limbic